DE3751809D1 - Intraoperative erstellung des befundes und tumor-therapie mittels endoskop - Google Patents

Intraoperative erstellung des befundes und tumor-therapie mittels endoskop

Info

Publication number
DE3751809D1
DE3751809D1 DE3751809T DE3751809T DE3751809D1 DE 3751809 D1 DE3751809 D1 DE 3751809D1 DE 3751809 T DE3751809 T DE 3751809T DE 3751809 T DE3751809 T DE 3751809T DE 3751809 D1 DE3751809 D1 DE 3751809D1
Authority
DE
Germany
Prior art keywords
intraoperative
endoscope
findings
creation
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE3751809T
Other languages
English (en)
Other versions
DE3751809T2 (de
Inventor
Milton Goldenberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunomedics Inc
Original Assignee
Immunomedics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunomedics Inc filed Critical Immunomedics Inc
Publication of DE3751809D1 publication Critical patent/DE3751809D1/de
Application granted granted Critical
Publication of DE3751809T2 publication Critical patent/DE3751809T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/42—Arrangements for detecting radiation specially adapted for radiation diagnosis
    • A61B6/4208—Arrangements for detecting radiation specially adapted for radiation diagnosis characterised by using a particular type of detector
    • A61B6/4258—Arrangements for detecting radiation specially adapted for radiation diagnosis characterised by using a particular type of detector for detecting non x-ray radiation, e.g. gamma radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Endoscopes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE3751809T 1986-12-18 1987-12-17 Intraoperative erstellung des befundes und tumor-therapie mittels endoskop Expired - Fee Related DE3751809T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/943,561 US4932412A (en) 1986-12-18 1986-12-18 Intraoperative and endoscopic tumor detection and therapy
PCT/US1987/003384 WO1988004537A1 (en) 1986-12-18 1987-12-17 Intraoperative and endoscopic tumor detection and therapy

Publications (2)

Publication Number Publication Date
DE3751809D1 true DE3751809D1 (de) 1996-06-20
DE3751809T2 DE3751809T2 (de) 1997-01-16

Family

ID=25479863

Family Applications (1)

Application Number Title Priority Date Filing Date
DE3751809T Expired - Fee Related DE3751809T2 (de) 1986-12-18 1987-12-17 Intraoperative erstellung des befundes und tumor-therapie mittels endoskop

Country Status (10)

Country Link
US (1) US4932412A (de)
EP (1) EP0335910B1 (de)
JP (1) JP2866093B2 (de)
AT (1) ATE137940T1 (de)
AU (1) AU615427B2 (de)
CA (1) CA1284769C (de)
DE (1) DE3751809T2 (de)
IL (1) IL84866A (de)
SG (1) SG46455A1 (de)
WO (1) WO1988004537A1 (de)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5084266A (en) * 1988-02-03 1992-01-28 The University Of Melbourne Method for tumor imaging utilizing a labelled tumor specific antibody and a non-tumor reactive antibody
CA1329119C (en) * 1988-03-29 1994-05-03 Milton David Goldenberg Cytotoxic therapy
CA1339415C (en) * 1989-08-24 1997-09-02 Milton David Goldenberg Detection and treatment of infections with immunoconjugates
DK176290D0 (da) * 1990-07-24 1990-07-24 Novo Nordisk As Terapeutisk og diagnostisk praeparat
US5398685A (en) * 1992-01-10 1995-03-21 Wilk; Peter J. Endoscopic diagnostic system and associated method
EP0643583B1 (de) * 1992-05-06 2000-07-26 Immunomedics, Inc. Intraoperative, intravaskulare und endoskopische bestimmung und behandlung von verletzungen und tumoren
US6096289A (en) * 1992-05-06 2000-08-01 Immunomedics, Inc. Intraoperative, intravascular, and endoscopic tumor and lesion detection, biopsy and therapy
US5590656A (en) * 1992-09-15 1997-01-07 The Ohio State University Research Foundation Application of peptide/cell receptor kinetics utilizing radiolabeled somatostatin congeners in the in situ, in vivo detection and differentiation of neoplastic tissue
US5441050A (en) * 1992-12-18 1995-08-15 Neoprobe Corporation Radiation responsive surgical instrument
US5482698A (en) * 1993-04-22 1996-01-09 Immunomedics, Inc. Detection and therapy of lesions with biotin/avidin polymer conjugates
US5657759A (en) * 1993-05-13 1997-08-19 Synectics Medical, Incorporated Measurement of gastric emptying and gastrointestinal output
US6120768A (en) * 1993-05-17 2000-09-19 Immunomedics, Inc. Dota-biotin derivatives
CA2163107C (en) * 1993-05-17 2001-04-17 David Milton Goldenberg Improved detection and therapy of lesions with biotin/avidin-metal chelating protein conjugates
AU1937195A (en) * 1994-03-02 1995-09-18 Mark Krakovitz Hybrid probes for characterizing diseases
US5482040A (en) * 1994-04-14 1996-01-09 The Ohio State University Research Foundation Biostaging of adenocarcinomas utilizing radiolabeled tumor-associated glycoprotein antibodies
US5746996A (en) * 1994-06-03 1998-05-05 Immunomedics, Inc. Thiolation of peptides for radionuclide-based radiodetection and radiotherapy
US5608520A (en) * 1994-07-11 1997-03-04 The United States Of America As Represented By He Department Of Energy Plasma emission spectroscopy method of tumor therapy
US5813985A (en) * 1995-07-31 1998-09-29 Care Wise Medical Products Corporation Apparatus and methods for providing attenuation guidance and tumor targeting for external beam radiation therapy administration
AU9661598A (en) * 1997-09-10 1999-03-29 Yale University Radiation dosimetry with magnetic resonance detectable compounds
US6207111B1 (en) * 1997-12-31 2001-03-27 Pem Technologies, Inc. System for describing the physical distribution of an agent in a patient
ATE473242T1 (de) 1998-05-20 2010-07-15 Immunomedics Inc Therapeutische mittel welche einen bispezifischen anti-hla class ii invariant chain x anti-pathogen antikörper enthalten
US6242741B1 (en) * 1998-10-23 2001-06-05 United States Surgical Corporation Radiation detection apparatus
WO2000059547A2 (en) * 1999-04-02 2000-10-12 Center For Molecular Medicine And Immunology Method of detecting endometriosis
US6167297A (en) * 1999-05-05 2000-12-26 Benaron; David A. Detecting, localizing, and targeting internal sites in vivo using optical contrast agents
US8383081B2 (en) * 1999-05-10 2013-02-26 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods of use
US7829064B2 (en) * 1999-05-10 2010-11-09 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods
US8119101B2 (en) * 1999-05-10 2012-02-21 The Ohio State University Anti-CD74 immunoconjugates and methods of use
US7373197B2 (en) * 2000-03-03 2008-05-13 Intramedical Imaging, Llc Methods and devices to expand applications of intraoperative radiation probes
US6602488B1 (en) 2000-03-03 2003-08-05 Intramedical Imaging, Llc Use of radiopharmaceuticals and intraoperative radiation probe for delivery of medicinal treatments
US6510336B1 (en) 2000-03-03 2003-01-21 Intra Medical Imaging, Llc Methods and devices to expand applications of intraoperative radiation probes
US7008633B2 (en) * 2000-12-18 2006-03-07 Board Of Regents, The University Of Texas System Local regional chemotherapy and radiotherapy using in situ hydrogel
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
AU2002303181A1 (en) * 2001-03-30 2002-10-15 University Of Massachusetts Morpholino imaging and therapy
US6993376B2 (en) * 2002-01-28 2006-01-31 Testardi Louis R Radiation measurement within the human body
US9770517B2 (en) 2002-03-01 2017-09-26 Immunomedics, Inc. Anti-Trop-2 antibody-drug conjugates and uses thereof
US7939304B2 (en) * 2002-10-02 2011-05-10 Catalyst Biosciences, Inc. Mutant MT-SP1 proteases with altered substrate specificity or activity
US20060024289A1 (en) * 2002-10-02 2006-02-02 Ruggles Sandra W Cleavage of VEGF and VEGF receptor by wild-type and mutant proteases
WO2004039233A2 (en) * 2002-10-31 2004-05-13 Given Imaging Ltd. System and method for in vivo detection of h. pylori
US8420086B2 (en) 2002-12-13 2013-04-16 Immunomedics, Inc. Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases
EP1660519B1 (de) * 2003-07-29 2014-05-14 Immunomedics, Inc. Konjugate von 2-[18F]Fluor-2-desoxy-D-glucose und einem Peptid-Molekül
AU2004263538B2 (en) * 2003-08-08 2009-09-17 Immunomedics, Inc. Bispecific antibodies for inducing apoptosis of tumor and diseased cells
DE602004025726D1 (de) * 2003-11-14 2010-04-08 Genvec Inc Pharmazeutische verbindung zur behandlung von lokal fortgeschrittenem primär inoperablen pankreaskarzinom (lapc).
US9550838B2 (en) 2004-02-13 2017-01-24 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
US8883160B2 (en) * 2004-02-13 2014-11-11 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
EP1733056B1 (de) 2004-03-31 2013-05-22 The General Hospital Corporation Verfahren zur bestimmung des ansprechens eines tumors auf behandlungen mit dem epidermalen wachstumsfaktor-rezeptor als target
CA2562729C (en) 2004-04-12 2013-11-12 Sandra Waugh Ruggles Cleavage of vegf and vegf receptor by wildtype and mutant mt-sp1
US7829291B2 (en) * 2005-02-17 2010-11-09 Vanderbilt University In situ analysis of tissues
US10058621B2 (en) 2015-06-25 2018-08-28 Immunomedics, Inc. Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
JP5214252B2 (ja) 2005-03-03 2013-06-19 イミューノメディクス、インコーポレイテッド ヒト化ｌ２４３抗体
US9707302B2 (en) 2013-07-23 2017-07-18 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
US8475794B2 (en) 2005-04-06 2013-07-02 Ibc Pharmaceuticals, Inc. Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
US8349332B2 (en) 2005-04-06 2013-01-08 Ibc Pharmaceuticals, Inc. Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
PT2298815E (pt) 2005-07-25 2015-07-16 Emergent Product Dev Seattle Moléculas de ligaçao especificas para cd37 e especificas para cd20
EP2674440B1 (de) 2005-12-16 2019-07-03 IBC Pharmaceuticals, Inc. Polyvalente bioaktive anordnungen auf immunglobulinbasis
MX2008015524A (es) * 2006-06-12 2009-01-13 Trubion Pharmaceuticals Inc Proteinas de union multivalentes monocatenarias con funcion efectora.
KR101476458B1 (ko) 2006-07-05 2015-01-05 카탈리스트 바이오사이언시즈, 인코포레이티드 프로테아제 스크리닝 방법 및 이에 의해 확인된 프로테아제
BRPI0814060A2 (pt) * 2007-07-06 2015-01-06 Trubion Pharmaceuticals Inc Peptídeos ligantes tendo um domínio de ligação específico disposto em c-terminal
AU2008302345A1 (en) * 2007-09-19 2009-03-26 Oncofluor, Inc. Method for imaging and treating organs and tissues
WO2009126944A1 (en) 2008-04-11 2009-10-15 Trubion Pharmaceuticals, Inc. Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
US9605844B2 (en) * 2009-09-01 2017-03-28 Cree, Inc. Lighting device with heat dissipation elements
WO2011085354A1 (en) * 2010-01-11 2011-07-14 Center For Molecular Medicine And Immunology Enhanced cytotoxicity of anti-cd74 and anti-hla-dr antibodies with interferon-gamma
US9757458B2 (en) 2011-12-05 2017-09-12 Immunomedics, Inc. Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells
EP2788020A4 (de) 2011-12-05 2015-04-29 Immunomedics Inc Therapeutische verwendung von anti-cd22-antikörpern zur induktion von trogozytose
US10517483B2 (en) 2012-12-05 2019-12-31 Accuvein, Inc. System for detecting fluorescence and projecting a representative image
US10413539B2 (en) 2012-12-13 2019-09-17 Immunomedics, Inc. Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)
US9931417B2 (en) 2012-12-13 2018-04-03 Immunomedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
US10206918B2 (en) 2012-12-13 2019-02-19 Immunomedics, Inc. Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
PL2900277T3 (pl) 2012-12-13 2022-05-16 Immunomedics, Inc. Dawkowanie immunokoniugatów przeciwciał i sn-38 dla poprawy skuteczności i zmniejszenia toksyczności
WO2015012904A2 (en) 2012-12-13 2015-01-29 Immunomedics, Inc. Antibody-sn-38 immunoconjugates with a cl2a linker
US10744129B2 (en) 2012-12-13 2020-08-18 Immunomedics, Inc. Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2
US9492566B2 (en) 2012-12-13 2016-11-15 Immunomedics, Inc. Antibody-drug conjugates and uses thereof
US10137196B2 (en) 2012-12-13 2018-11-27 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
US11253606B2 (en) 2013-07-23 2022-02-22 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
EP3268362B1 (de) 2015-03-11 2021-10-20 Peloton Therapeutics, Inc. Substituierte pyridine und verwendungen davon
JP6746845B2 (ja) 2015-04-22 2020-08-26 イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． 循環ｔｒｏｐ−２陽性癌細胞の単離、検出、診断及び／または特徴付け
US10195175B2 (en) 2015-06-25 2019-02-05 Immunomedics, Inc. Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
MY197562A (en) 2015-09-21 2023-06-23 Aptevo Res & Development Llc Cd3 binding polypeptides
CA3002381A1 (en) 2015-10-21 2017-04-27 Teclison Limited Compositions and methods for immune-mediated cancer therapy
CN108601841A (zh) 2016-02-10 2018-09-28 免疫医疗公司 Abcg2抑制剂与sacituzumab govitecan(immu-132)的组合克服表达trop-2的癌中对sn-38的抗性
EP3448260A4 (de) 2016-04-27 2019-10-09 Immunomedics, Inc. Wirksamkeit von anti-trop-2-sn-38-antikörper-wirkstoff-konjugaten zur therapie von rezidivierten/refraktären tumoren gegen checkpoint-inhibitoren
EP3600283A4 (de) 2017-03-27 2020-12-16 Immunomedics, Inc. Behandlung von trop-2-exprimierendem triple-negativem brustkrebs mit sacituzumab govitecan und einem rad51-hemmer
WO2018187074A1 (en) 2017-04-03 2018-10-11 Immunomedics, Inc. Subcutaneous administration of antibody-drug conjugates for cancer therapy
EP3810109A4 (de) 2018-05-31 2022-03-16 Peloton Therapeutics, Inc. Zusammensetzungen und verfahren zur hemmung von cd73
JP7425794B2 (ja) 2018-10-30 2024-01-31 ペロトン セラピューティクス， インコーポレイテッド 置換されたインダンを含む固体分散体及び医薬組成物並びにそれの製造方法及び使用
US11625825B2 (en) 2019-01-30 2023-04-11 Covidien Lp Method for displaying tumor location within endoscopic images
JP2023512214A (ja) 2020-01-28 2023-03-24 リフレクション メディカル， インコーポレイテッド 放射性核種および外部ビーム放射線療法の共同最適化
BR112022023199A2 (pt) 2020-05-15 2023-04-04 Algen Biotechnologies Inc Certas composições químicas e métodos de uso das mesmas

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5552750A (en) * 1978-10-12 1980-04-17 Mochida Pharm Co Ltd Laser knife* which can be detected* of tumor portion
US4361544A (en) * 1980-03-03 1982-11-30 Goldenberg Milton David Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
US4444744A (en) * 1980-03-03 1984-04-24 Goldenberg Milton David Tumor localization and therapy with labeled antibodies to cell surface antigens
US4460559A (en) * 1980-03-03 1984-07-17 Goldenberg Milton David Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
US4348376A (en) * 1980-03-03 1982-09-07 Goldenberg Milton David Tumor localization and therapy with labeled anti-CEA antibody
US4460561A (en) * 1980-03-03 1984-07-17 Goldenberg M David Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
US4431626A (en) * 1981-05-27 1984-02-14 The Regents Of The University Of California Tc-99m Labeled carrier for imaging
US4624846A (en) * 1983-07-29 1986-11-25 Immunomedics, Inc. Method for enhancing target specificity of antibody localization and clearance of non-target diagnostic and therapeutic principles
US4595014A (en) * 1983-10-18 1986-06-17 University Patents, Inc. Imaging probe and method
US4782840A (en) * 1984-03-02 1988-11-08 Neoprobe Corporation Method for locating, differentiating, and removing neoplasms

Also Published As

Publication number Publication date
WO1988004537A1 (en) 1988-06-30
CA1284769C (en) 1991-06-11
AU1087988A (en) 1988-07-15
JP2866093B2 (ja) 1999-03-08
EP0335910B1 (de) 1996-05-15
EP0335910A1 (de) 1989-10-11
US4932412A (en) 1990-06-12
IL84866A0 (en) 1988-06-30
ATE137940T1 (de) 1996-06-15
DE3751809T2 (de) 1997-01-16
EP0335910A4 (de) 1990-03-05
SG46455A1 (en) 1998-02-20
IL84866A (en) 1992-09-06
AU615427B2 (en) 1991-10-03
JPH02502966A (ja) 1990-09-20

Similar Documents

Publication Publication Date Title
DE3751809D1 (de) Intraoperative erstellung des befundes und tumor-therapie mittels endoskop
ATE369425T1 (de) Antikörper gegen eine lar-phosphatase untereinheit
CY1109125T1 (el) Θεραπευτικα και διαγνωστικα anti-hsp 70 αντισωματα
NO175944C (no) Monoklonale antistoffer for anvendelse til in vitro påvisning av tumorassosiert mucinantigen, og hybridomcellelinjer som produserer disse
CY1113247T1 (el) Νουκλεϊνικα οξεα με τιτλο 273ρ4β7 και η χρηση τους στην ανιχνευση καρκινου
ATE194660T1 (de) Veraendertes gen bei menschlichem colorektalem- krebs
HUP0302532A2 (hu) Petefészekrák terápiájában és diagnosztizálásában alkalmazható készítmények és eljárások
ID22689A (id) Metode untuk mengaktifkan sel-sel yang menunjukan-sifat antigen manusia, sel-sel teraktifkan yang menunjukan sifat antigen manusia, dan penggunaannya
SE8000435L (sv) N-bensylimidazoler med selektivt inhiberande verkan pa tromboxansyntetasenzymet jemte farmaceutiska beredningar innehallande sadana n-bensylimidazoler och sett for deras framstellning
AR031250A1 (es) Composiciones y metodos para la terapia y el diagnostico del cancer de pulmon
EP0232871A3 (de) Menschlicher monoklonaler Antikörper, Hybridoma zu seiner Herstellung und seine Verwendung
FI891718A (fi) Foerfarande foer att befria cellblandningar och vaevnader av icke-oenskade populationer.
FI101597B1 (fi) Menetelmä kylmäkuivatun koostumuksen valmistamiseksi käytettäväksi potilaan valodynaamisessa hoidossa tai diagnosoinnissa
EA199900775A1 (ru) Быстрый способ диагностики рака
ATE134874T1 (de) Synoviale phospholipasen
DK0495910T3 (da) Fremstilling og anvendelse af humant nm23-H2-protein og derimod rettede antistoffer
NO20004250D0 (no) Humaniserte anti-TAG-72 monoklonale antistoffer med høy affinitet
GR880100589A (en) Metalloporfyrines for the inversion of the toxic activity for the tumors treatment
SU540063A1 (ru) Гидроцилиндр одностороннего действи
SE7700173L (sv) 2-oxo-1-pyrrolidin och forfarande for framstellning derav
SU571521A1 (ru) Способ термической обработки листовых деталей
ATE291620T1 (de) Mammakarzinom-assoziiertes gen
SU530895A1 (ru) Эпоксидна композици
SU566560A1 (ru) Способ кавернографии
RU96120456A (ru) Способ рентгендиагностики рака вульвы

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee